Jayne Tierney, Professor of Evidence Synthesis
Jayne has been at the Unit since it was formed in 1999, and prior to that, in the Cancer Trials Office in Cambridge. For more than 20 years, she has been responsible for designing and conducting systematic reviews and meta-analysis to rigorously re-evaluate the effectiveness of therapies; projects that have influenced practice guidelines and the treatment of patients worldwide.
She leads a small group that has published international, collaborative, individual participant data (IPD) reviews in bladder, cervix, lung, oesophagus, and soft-tissue cancer, and advised on projects in pregnancy and wound care. In addition, she has been involved in systematic reviews of aggregate data in stroke, HIV, and fertility medicine, as well as in cancer. New projects are underway to evaluate the effects of therapies for prostate cancer.
Jayne is also involved in methodological research to try to improve how systematic reviews and meta-analyses are conducted and analysed. Current interests include how to do timely and reliable aggregate data meta-analyses, and how best to evaluate treatment covariate interaction in meta-analysis. Jayne also provides advice and training on systematic review methods, and is Deputy Director of the London Hub for Trials Methodology Research.
Jayne has been involved in Cochrane since its beginnings, providing peer review for Cochrane Review Groups and workshops at annual meetings and colloquia. She is one of the co-convenors of the IPD Meta-analysis Methods Group.
Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?. BMJ 2017, 356 j573
Rydzewska LHM, Burdett S, Vale CL,... Tierney JF. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.. Eur J Cancer 2017; 84;88-101.
Vale CL, Burdett S, Rydzewska LHM, …, Tierney JF, for the STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016; 17:243-56.
Tierney JF, Vale C, Riley R, Tudur Smith C, Stewart L, Clarke M, Rovers M. Individual participant data (IPD) meta-analyses of randomised controlled trials: Guidance on their use, PLoS Med 12: e1001855.
Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G. Tierney JF. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement. JAMA 2015; 313(16):1657-1665.